These findings are supported by transcriptomic data from the Accelerating Medicines Partnership-Alzheimer’s disease (AMP-AD) consortium showing a significant upregulation of P2RX7 mRNA in AD relative to controls as well as in CRND8 (mutant human APP) and rTg4510 (mutant human tau) -expressing transgenic mice with ageing. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.